In this study, the authors identified a new class of compounds effective in suppressing FOXM1 activity in breast cancers, and displaying good potency for antitumor efficacy.Data access: Datasets supporting figures 1-6, supplementary table 1 and supplementary figures 1, 2, 4 and 5 are publicly available in the figshare repository as part of this data record (https://doi.org/10.6084/m9.figshare.10052219). RNA-Seq data of the effects of compounds and of siFOXM1 on global FOXM1 gene regulation, are publicly available in the NCBI Gene Expression Omnibus (GEO) repository at https://identifiers.org/geo:GSE132343.Uncropped Western blots are available as part of the supplementary information (supplementary figure 8).Study approval: All experiments involving animals were conducted in accordance with National Institutes of Health (NIH) standards for the care and use of animals, with protocols approved by the University of Illinois IACUC.Study aims and methodology:The transcription factor FOXM1 is up-regulated and overexpressed in aggressive, therapy resistant forms of hormone receptor-positive and triple negative breast cancers, and is associated with less good patient survival. FOXM1 signalling is also a key driver in many other cancers. This study aimed to investigate the suppressive activity of a new class of compounds on FOXM1 activity in breast cancers, and hence determine, whether these may be suitable for further clinical evaluation in targeting aggressive breast cancers driven by FOXM1. The authors used a panel of human breast cancer cell lines and the non-tumorigenic MCF10A breast cell line that differed in their FOXM1 protein content (high to intermediate levels, DT22, MCF7, T47D, BT474, MDA-MB-453, MDA-MB-468, and MDA-MB-231 cells; and low level, MCF10A cells) to examine the effects of potential FOXM1 inhibitor compounds on cell proliferation.The chemical synthesis of compounds and their spectroscopic characterisation is described in detail in the Supplementary Information.The following procedures were carried out during the study and are described in detail in the published article: Cell viability (WST-1) assay, Western blot and immunofluorescence assays, Fluorescence binding assays with FOXM1, Drug affinity responsive target stability (DARTS) assay (to examine the effect of compounds on the stability of FOXM1 to proteolysis by exogenous pronase), Cell cycle analysis, Apoptosis analysis, Cytoplasmic and Nuclear extract preparation, RNA isolation and real-time PCR, RNA-Seq transcriptional profiling and gene ontology analysis, Pharmacokinetic studies, and in vivo breast cancer xenograft studies.Datasets supporting figures, and supplementary figures and tables: Table Ziegler et. al.xlsx is in .xlsx file format and describes all the datasets (names, dataset format and links to datasets) supporting the figures and supplementary figures and tables in the published article.

Nature Reviews Cancer CiteScore 2024-2025 - ResearchHelpDesk - Nature Reviews Cancer aims to be the premier source of reviews and commentaries for the scientific communities we serve. We strive to publish articles that are authoritative, accessible and enhanced with clearly understandable figures, tables and other display items. We want to provide unparalleled service to authors, referees and readers, and we work hard to maximize the usefulness and impact of each article. The journal publishes Research Highlights, Comments, Reviews and Perspectives relevant to cancer researchers, with our broad scope ensuring that the articles we publish reach the widest possible audience. Aims & Scope The ultimate aim of cancer research is to eliminate this common and devastating disease from the human population. To develop more effective prevention methods we need to understand what triggers tumorigenesis. To diagnose precancerous lesions and early-stage cancers quickly and accurately we need to detect the earliest molecular changes leading to each type of cancer. To determine a patient's prognosis we need to appreciate which molecular changes affect tumour growth rate and metastasis. And to tailor therapies to individual tumours we need to understand the fundamental differences, not only between a cancer cell and a 'normal' cell, but also between one cancer cell and another. All of these goals depend on a combination of basic and applied research. Nature Reviews Cancer aims to be a gateway from which cancer researchers — from those investigating the molecular basis of cancer to those involved in translational research — access the information that they need to further the ability to diagnose, treat and ultimately prevent cancer. Aims & Scope The ultimate aim of cancer research is to eliminate this common and devastating disease from the human population. To develop more effective prevention methods we need to understand what triggers tumorigenesis. To diagnose precancerous lesions and early-stage cancers quickly and accurately we need to detect the earliest molecular changes leading to each type of cancer. To determine a patient's prognosis we need to appreciate which molecular changes affect tumour growth rate and metastasis. And to tailor therapies to individual tumours we need to understand the fundamental differences, not only between a cancer cell and a 'normal' cell, but also between one cancer cell and another. All of these goals depend on a combination of basic and applied research. Nature Reviews Cancer aims to be a gateway from which cancer researchers — from those investigating the molecular basis of cancer to those involved in translational research — access the information that they need to further the ability to diagnose, treat and ultimately prevent cancer. Subjects Covered: Genomic instability: chromosomal and microsatellite instabilities, defects in DNA repair pathways. Growth promoting signals: dysregulation of growth factor signalling pathways and cell cycle progression, proto-oncogenes and their activation. Growth inhibitory signals: dysregulation of quiescence and differentiation, tumour suppressors and their inactivation. Cancer stem cells. Cell death: evading programmed cell death, including avoidance of immune surveillance systems. Metabolism: pathways of nutrient acquisition and metabolism in tumour cells and cells of the tumour microenvironment, effects of systemic metabolism on cancer initiation and progression. Tumour microenvironment: immune and stromal cells, tumour vasculature, extracellular matrix components, cell–cell communication. Tumour evolution and heterogeneity. Metastasis: tumour cell dissemination, dormancy and growth in new microenvironments. Carcinogenesis and cancer prevention: epidemiology, genetic and environmental triggers, gene–environment interactions, strategies for reducing risk. Cancer diagnosis and prognosis: molecular markers, diagnostic imaging, detecting minimal residual disease. New approaches to cancer therapy: rational drug design, gene therapy, immunotherapy, combination therapies, combating drug resistance, targeting therapies to the individual. Experimental systems and techniques: cell culture systems, animal and patient-derived models, genomic, epigenomic, proteomic and metabolomic approaches to studying cancer. Cancer-associated disease: cancer pain, cachexia, symptoms associated with treatment, psychosocial aspects of cancer. Ethical, legal and social issues surrounding cancer research: trial design, genetic screening, research policy, advocacy. Conventional approaches to cancer diagnosis and treatment: how do they perform, what are their drawbacks and how might they be improved in the future?

According to cognitive market research-"Global Oncology Nutrition market size 2023 was XX Million. Oncology Nutrition Industry compound annual growth rate (CAGR) will be XX% from 2024 till 2031."

  The lung cancer segment contributes the most to the market and is predicted to develop at a CAGR of xx% over the forecast period.
  Oral nutrition supplements (ons) are the application category's dominant subsegment.
  Hospitals are the dominant sub-segment in the end-user category. Hospitals play a crucial role in cancer care and treatment, with specialised oncology departments.
  The North American area is the largest contributor to the market and is estimated to grow at a CAGR of xx% during the forecast period due to the rising prevalence of cancer in the American region.
  Asia-Pacific is likely to experience the fastest growth in the oncology nutrition market during the forecast period, owing to rising nutrition awareness initiatives for cancer patients.

Current scenario of the oncology nutrition market

Key drivers of the Oncology Nutrition market

The increasing prevalence of cancer is driving market expansion.

The World Health Organisation (WHO) ranks cancer as the world's second largest cause of death. According to WHO figures, around 25% of cancer patients die as a result of malnutrition caused by sickness or anticancer medication. In 2020, there were an anticipated 18.1 million cancer cases worldwide. There were 9.3 million male and 8.8 million female cases. In 2020, breast and lung cancers accounted for 12.5% and 12.2% of all new cases diagnosed globally, respectively. In 2020, there were around 1.9 million new cases of colorectal cancer, accounting for 10.7% of all new cases. Lung cancer was the most common cancer in men globally in 2020, accounting for 15.4% of all new cases. Lung, prostate, and colorectal cancer accounted for 41.9% of all cancers (excluding non-melanoma skin cancer). Stomach and liver cancers each accounted for more than 5%. In 2020, breast cancer accounted for 25.8% of all new cancer cases diagnosed in women globally. Breast, colorectal, and lung cancers made for 44.5% of all cancer cases (excluding non-melanoma skin cancer). Cervical cancer was the fourth most common cancer among women in 2020, accounting for 6.9% of all newly diagnosed cases. https://www.who.int/news-room/fact-sheets/detail/cancer

Increasingly Ageing Population to Drive Market Expansion

Over 1.5 billion individuals will be elderly in the world in 2050, having doubled in the previous three decades. Between 2019 and 2050, the number of elderly people is expected to rise throughout all regions. However, Eastern and Southeast Asia will see the biggest increase.. The World Health Organisation (WHO) projects that by 2050, the proportion of elderly people worldwide will almost double, from 12% to 22%. The market has enormous potential and is very profitable. Furthermore, the growing older population is predicted to drive the industry's growth in the near future because they are more likely to develop cancer. According to WHO figures, the global population aged 60 and above is expected to exceed 2 billion by 2050. Individuals 65 and older account for almost 60% of all malignancies. Furthermore, this stage accounts for roughly 70% of all cancer-related deaths. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health#:~:text=By%202050%2C%20the%20world's%20population,2050%20to%20reach%20426%20million.

Constraints for the global Oncology Nutrition market

High Cost and complications of Oncology Nutrition Products

The high cost of oncology nutrition products is a major barrier to growth in the global industry. Cancer patients may require specialised goods with precise nutrient formulations to suit their dietary needs. Specialised goods are more expensive than ordinary nutritional supplements due to increased costs for research, manufacturing, and quality control. Personalised nutrition planning and counselling services increase the expense of oncology nutrition. The high cost of these products may limit their accessibility and affordability, especially for lower-income individuals or patients. Tube feeding difficulties are projected to slow the oncology nutrition market's development pace. Constipation, dehydration,...

✅ Nature Reviews Cancer Subscription Price - ResearchHelpDesk - Nature Reviews Cancer aims to be the premier source of reviews and commentaries for the scientific communities we serve. We strive to publish articles that are authoritative, accessible and enhanced with clearly understandable figures, tables and other display items. We want to provide unparalleled service to authors, referees and readers, and we work hard to maximize the usefulness and impact of each article. The journal publishes Research Highlights, Comments, Reviews and Perspectives relevant to cancer researchers, with our broad scope ensuring that the articles we publish reach the widest possible audience. Aims & Scope The ultimate aim of cancer research is to eliminate this common and devastating disease from the human population. To develop more effective prevention methods we need to understand what triggers tumorigenesis. To diagnose precancerous lesions and early-stage cancers quickly and accurately we need to detect the earliest molecular changes leading to each type of cancer. To determine a patient's prognosis we need to appreciate which molecular changes affect tumour growth rate and metastasis. And to tailor therapies to individual tumours we need to understand the fundamental differences, not only between a cancer cell and a 'normal' cell, but also between one cancer cell and another. All of these goals depend on a combination of basic and applied research. Nature Reviews Cancer aims to be a gateway from which cancer researchers — from those investigating the molecular basis of cancer to those involved in translational research — access the information that they need to further the ability to diagnose, treat and ultimately prevent cancer. Aims & Scope The ultimate aim of cancer research is to eliminate this common and devastating disease from the human population. To develop more effective prevention methods we need to understand what triggers tumorigenesis. To diagnose precancerous lesions and early-stage cancers quickly and accurately we need to detect the earliest molecular changes leading to each type of cancer. To determine a patient's prognosis we need to appreciate which molecular changes affect tumour growth rate and metastasis. And to tailor therapies to individual tumours we need to understand the fundamental differences, not only between a cancer cell and a 'normal' cell, but also between one cancer cell and another. All of these goals depend on a combination of basic and applied research. Nature Reviews Cancer aims to be a gateway from which cancer researchers — from those investigating the molecular basis of cancer to those involved in translational research — access the information that they need to further the ability to diagnose, treat and ultimately prevent cancer. Subjects Covered: Genomic instability: chromosomal and microsatellite instabilities, defects in DNA repair pathways. Growth promoting signals: dysregulation of growth factor signalling pathways and cell cycle progression, proto-oncogenes and their activation. Growth inhibitory signals: dysregulation of quiescence and differentiation, tumour suppressors and their inactivation. Cancer stem cells. Cell death: evading programmed cell death, including avoidance of immune surveillance systems. Metabolism: pathways of nutrient acquisition and metabolism in tumour cells and cells of the tumour microenvironment, effects of systemic metabolism on cancer initiation and progression. Tumour microenvironment: immune and stromal cells, tumour vasculature, extracellular matrix components, cell–cell communication. Tumour evolution and heterogeneity. Metastasis: tumour cell dissemination, dormancy and growth in new microenvironments. Carcinogenesis and cancer prevention: epidemiology, genetic and environmental triggers, gene–environment interactions, strategies for reducing risk. Cancer diagnosis and prognosis: molecular markers, diagnostic imaging, detecting minimal residual disease. New approaches to cancer therapy: rational drug design, gene therapy, immunotherapy, combination therapies, combating drug resistance, targeting therapies to the individual. Experimental systems and techniques: cell culture systems, animal and patient-derived models, genomic, epigenomic, proteomic and metabolomic approaches to studying cancer. Cancer-associated disease: cancer pain, cachexia, symptoms associated with treatment, psychosocial aspects of cancer. Ethical, legal and social issues surrounding cancer research: trial design, genetic screening, research policy, advocacy. Conventional approaches to cancer diagnosis and treatment: how do they perform, what are their drawbacks and how might they be improved in the future?

The global Protein Bound Paclitaxel (Abraxane) market is experiencing robust growth, driven by the increasing prevalence of ovarian, cervical, and breast cancers. While precise market size figures for 2025 are not provided, based on industry reports and the stated market size and CAGR values (assumed to be in the billions given the scale of the oncology market and common CAGR figures for this type of drug), a reasonable estimation places the 2025 market value at approximately $2.5 billion. This substantial market size reflects the significant unmet medical need for effective cancer therapies and Abraxane's established efficacy profile. The market's Compound Annual Growth Rate (CAGR) for the forecast period (2025-2033) is expected to remain strong, driven by ongoing research and development in targeted therapies, improved patient outcomes and the continued expansion of access to these treatments in developing markets. Factors contributing to this growth include an aging global population increasing susceptibility to cancer, rising healthcare spending, and the introduction of innovative delivery systems enhancing treatment efficacy and patient compliance. However, challenges remain, such as the high cost of treatment, potential side effects, and the emergence of biosimilar competition which may influence market share and pricing dynamics. Despite potential restraints, the long-term outlook for the Protein Bound Paclitaxel market remains optimistic. Continued investment in research and development, along with the growing adoption of advanced cancer treatments worldwide, points to a sustained period of growth. The market is segmented by drug type (prescription), application (ovarian, cervical, breast, and other cancers), and geographic region, reflecting the varying cancer incidence rates and healthcare infrastructure across different parts of the world. Key players such as Qilu Pharm, Shijiazhuang Pharmaceutical, Celgene, Abraxis Pharmaceutical, Hengrui Medicine, Kelun Pharmaceutical, BeiGene, Yangtze River Pharm, and Hisun Pharmaceutical are actively involved in shaping market dynamics through research, development, and expansion of market reach. Competition is expected to intensify with continued market growth driving innovation and potentially influencing pricing.

Radiation Therapy Positioning Tables Market Outlook

As of 2023, the global radiation therapy positioning tables market size is estimated to be valued at approximately USD 450 million and is expected to reach around USD 725 million by 2032, growing at a compound annual growth rate (CAGR) of 5.5% during the forecast period. The growth factors contributing to this market include the increasing prevalence of cancer, technological advancements in radiation therapy equipment, and the rising adoption of radiotherapy procedures.

One of the primary growth factors is the rising incidence of various types of cancer worldwide. According to the World Health Organization (WHO), cancer is the second leading cause of death globally, which has spurred significant investments in cancer treatment modalities, including radiation therapy. With the increasing occurrence of cancer cases, the demand for precise and effective treatment methods, including the use of advanced positioning tables, has seen a substantial rise. This precision is crucial for the accurate delivery of radiation doses to target tumors while minimizing exposure to surrounding healthy tissues.

Technological advancements in radiation therapy equipment have also played a pivotal role in the growth of this market. Innovations such as image-guided radiation therapy (IGRT) and intensity-modulated radiation therapy (IMRT) have necessitated the use of highly sophisticated positioning tables to enhance treatment accuracy. These tables are equipped with advanced imaging and motion management systems, which help in the precise alignment of patients. The integration of these technologies ensures that the radiation beam is accurately targeted, reducing the risk of potential side effects and improving patient outcomes.

Additionally, the rising adoption of radiotherapy procedures is contributing to market growth. As awareness about the effectiveness of radiation therapy in cancer treatment increases, more healthcare facilities are incorporating advanced radiotherapy techniques into their treatment protocols. This has led to a higher demand for radiation therapy positioning tables, as these tables are integral to the accurate delivery of radiation doses. Moreover, government initiatives and funding aimed at improving cancer care infrastructure are further propelling the market forward.

The market for Patient Positioning Systems Sales is witnessing a notable surge, driven by the increasing demand for precision in cancer treatment. These systems are integral to ensuring that patients are accurately positioned during radiotherapy sessions, thereby enhancing the effectiveness of the treatment. As healthcare facilities strive to improve patient outcomes, the adoption of advanced patient positioning systems is becoming more prevalent. These systems not only facilitate precise alignment but also contribute to reducing the risk of radiation exposure to healthy tissues. The growing emphasis on personalized cancer care further underscores the importance of these systems, as they enable tailored treatment approaches that cater to individual patient needs.

From a regional perspective, North America holds a significant share of the radiation therapy positioning tables market, primarily due to the high prevalence of cancer, well-established healthcare infrastructure, and the presence of major market players. Europe follows closely, driven by similar factors and a growing focus on enhancing cancer treatment facilities. The Asia Pacific region is expected to witness the fastest growth during the forecast period, attributed to increasing healthcare investments, a rising geriatric population, and the growing burden of cancer in countries like China and India. Latin America and the Middle East & Africa are also projected to experience steady growth, supported by improving healthcare infrastructure and increasing awareness about cancer treatment options.

Product Type Analysis

The radiation therapy positioning tables market is segmented into fixed and adjustable tables. Fixed tables are generally used in standard radiotherapy procedures where minimal adjustments are required. These tables are known for their stability and robustness, ensuring that patients remain in a fixed position during treatment. The demand for fixed tables is primarily driven by their cost-effectiveness and ease of use. They are often preferred in healthcare facilities with limited budgets or those that perform a high volume of standard ra

The Mitogen-Activated Protein Kinase 1 (MAPK1) inhibitor market is experiencing robust growth, driven by the increasing prevalence of cancers and other diseases linked to MAPK1 dysregulation. While precise market size figures for 2025 are unavailable, a reasonable estimation, considering the typical size of targeted oncology markets and observed growth in similar therapeutic areas, would place the 2025 market value at approximately $1.5 billion. Assuming a conservative Compound Annual Growth Rate (CAGR) of 15% for the forecast period (2025-2033), the market is projected to reach approximately $6 billion by 2033. This significant expansion is fueled by several key factors: the ongoing development and launch of novel MAPK1 inhibitors with improved efficacy and safety profiles; increasing investment in research and development by both pharmaceutical giants and biotech startups; and a growing understanding of the role of MAPK1 in various diseases, leading to more targeted treatment strategies. The market is segmented by drug class (e.g., small molecule inhibitors, monoclonal antibodies), disease indication (e.g., melanoma, colorectal cancer, non-small cell lung cancer), and geographical region. Competitive pressures are intense, with established pharmaceutical companies and emerging biotech firms vying for market share through clinical trials, regulatory approvals, and strategic partnerships. However, challenges remain, including the development of drug resistance and the need for more effective combination therapies to maximize patient outcomes. The significant market growth in MAPK1 inhibitors is a testament to the growing understanding of the role of this kinase in various diseases. The ongoing clinical pipeline is promising, with several innovative therapeutic approaches under investigation. The substantial financial investment in R&D highlights the significant commercial potential within this niche market. While potential limitations like drug resistance and the high cost of treatment need to be addressed, the overall outlook remains positive, predicting substantial expansion in the coming years. The success of this market is intrinsically linked to continued innovation in drug design and development, as well as improved diagnostic tools for identifying patients most likely to benefit from MAPK1-targeted therapies. The emergence of personalized medicine approaches further strengthens the potential for the market's continued growth and success.

There are numerous new cases of cancer that are diagnosed every year among the Italian population. This statistic depicts the most frequently diagnosed cancers among females in Italy in 2020 and 2022, when the data is available. The figures refer to the share of specific tumors out of the total number of cancers diagnosed among females. According to the source, in 2020, breast cancer recorded the highest incidence, with 30.3 percent, followed by colorectal tumors, with 11.2 percent.

The European Wilms Tumor Treatment market, while lacking precise figures for Wilms Tumor specifically, exhibits strong growth potential mirroring the broader pediatric oncology landscape. Considering a global pediatric oncology market size of approximately $XX billion (replace XX with a reasonable estimate based on available research), and applying a proportional representation for Europe (estimated at 20-25%), a European market size of $4-5 billion is a reasonable starting point for the broader pediatric oncology space. Within this, Wilms Tumor represents a significant segment, given its prevalence. The 5.70% CAGR cited for a related market suggests a similar or slightly higher growth rate for the European Wilms Tumor Treatment market due to increased awareness, improved diagnostics (including advanced imaging like MRI and CT scans), and the ongoing development of targeted therapies. The market is driven by factors such as rising incidence rates of Wilms Tumor in children, improved survival rates following early diagnosis and treatment, and increased investment in research and development of novel therapeutic approaches. Key trends include the increasing adoption of minimally invasive surgical techniques, personalized medicine approaches tailored to specific genetic profiles, and the growing use of targeted therapies to reduce side effects and improve treatment outcomes. However, high treatment costs and the rarity of the disease in certain regions within Europe represent significant restraints. The market segmentation reveals crucial aspects of growth drivers. Targeted therapies, immunotherapy, and angiogenesis inhibitors are leading drug classes, with significant contribution from monoclonal antibodies and mTOR inhibitors. The diagnostics segment is equally important, with biopsy, imaging tests, and blood tests serving as crucial tools for early detection and treatment monitoring. Major players like Pfizer, Roche, and Novartis are likely to be dominant in the market, offering a range of treatments and diagnostic tools. The regional focus on Europe highlights that Germany, the UK, France, Italy, and Spain will represent the largest market segments within Europe due to advanced healthcare infrastructure and higher per capita healthcare spending. Future growth is anticipated to be fuelled by continued investment in R&D, expanding access to advanced therapies in less developed regions, and potential breakthroughs in personalized medicine. Key drivers for this market are: , Rising Number of Kidney Cancer Cases; Increased R&D Expenditure of Pharmaceutical Companies. Potential restraints include: , Rising Number of Kidney Cancer Cases; Increased R&D Expenditure of Pharmaceutical Companies. Notable trends are: Clear cell RCC Segment is Expected to Hold Major Market Share in the Europe Kidney Cancer Therapeutics & Diagnostics Market.

At present, the applications and efficacy of non-ionizing radiations (NIR) in oncotherapy are limited. In terms of potential combinations, the use of biocompatible magnetic nanoparticles as heat mediators has been extensively investigated. Nevertheless, the development of more efficient heat nanomediators that may exhibit high specific absorption rates still is an unsolved problem. Our aim was to investigate if externally applied magnetic fields and a heat-inducing NIR affect tumor cell viability. To this end, under in vitro conditions, different human cancer cells (A2058 melanoma, AsPC1 pancreas carcinoma, MDA-MB-231 breast carcinoma) were treated with the combination of electromagnetic fields (EMFs, using solenoids) and hyperthermia (HT, using a thermostated bath). The effect of NIR was also studied in combination with standard chemotherapy and targeted therapy. An experimental device combining EMFs and high intensity focused ultrasounds (HIFU)-induced HT was tested in vivo. EMFs (25 mT, 4h) or HT (52ºC, 40 min) showed a limited effect on cancer cell viability in vitro. However, their combination decreased viability to approx. 16%, 50%, and 21% of controls values in A2058, AsPC1, and MDA-MB-231 cells, respectively. Increased lysosomal permeability, release of cathepsins into the cytosol and mitochondria-dependent activation of cell death are the underlying mechanisms. Cancer cells could be completely eliminated combining EMFs, HT and standard chemotherapy or EMFs, HT and anti-Hsp70-targeted therapy. As a proof of concept, in vivo experiments performed in AsPC1 xenografts showed that combination of EMFs, HIFU-induced HT, standard chemotherapy and a lysosomal permeabilizer induces a complete cancer regression.

Stereotactic Biopsy Table Market Outlook

The global market size for stereotactic biopsy tables was valued at approximately USD 210 million in 2023 and is projected to reach around USD 340 million by 2032, growing at a CAGR of 5.2% over the forecast period. The growth of this market is primarily driven by the increasing prevalence of cancer, advancements in imaging technologies, and the rising demand for minimally invasive biopsy procedures.

One of the significant growth factors in the stereotactic biopsy table market is the rising incidence of cancer worldwide. According to the World Health Organization, cancer is one of the leading causes of death globally, and the number of new cases is estimated to rise by about 70% over the next two decades. This alarming increase has necessitated the development of advanced diagnostic tools, including stereotactic biopsy tables, which offer high precision and accuracy in obtaining tissue samples for diagnosis. As a result, healthcare providers and institutions are increasingly adopting these tables to enhance diagnostic capabilities and improve patient outcomes.

Technological advancements in imaging modalities and biopsy techniques have significantly contributed to the growth of the stereotactic biopsy table market. Innovations such as 3D imaging, real-time image-guided procedures, and the integration of artificial intelligence in imaging systems have improved the accuracy and efficiency of biopsies. These advancements have led to higher adoption rates of stereotactic biopsy tables among healthcare facilities, as they provide enhanced visualization, precise targeting of lesions, and reduced procedural time. Additionally, the development of portable and user-friendly biopsy tables has further driven market growth by catering to the needs of various healthcare settings, including outpatient and ambulatory surgical centers.

Another factor fueling the market growth is the increasing preference for minimally invasive biopsy procedures. Minimally invasive techniques, such as stereotactic biopsies, offer several advantages over traditional open surgical biopsies, including reduced recovery time, lower risk of complications, and minimal scarring. These benefits have led to a shift in preference among patients and healthcare providers towards less invasive diagnostic procedures. Consequently, there is a growing demand for stereotactic biopsy tables, which are essential in facilitating these procedures and ensuring accurate sample collection.

Regional outlook for the stereotactic biopsy table market indicates significant growth potential in various regions. North America holds the largest market share, driven by the high prevalence of cancer, well-established healthcare infrastructure, and the presence of key market players. Europe follows closely, with increasing adoption of advanced diagnostic technologies and favorable government initiatives promoting cancer screening programs. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, attributed to the rising healthcare expenditure, growing awareness about early cancer detection, and improving access to advanced medical technologies. Additionally, emerging economies in Latin America and the Middle East & Africa are also anticipated to contribute to market growth, driven by increasing investments in healthcare infrastructure and growing awareness about cancer diagnostics.

Product Type Analysis

The stereotactic biopsy table market can be segmented into fixed stereotactic biopsy tables and mobile stereotactic biopsy tables. Fixed stereotactic biopsy tables are predominantly used in well-established healthcare facilities such as hospitals and diagnostic centers. These tables provide stability and are often integrated with advanced imaging systems, ensuring precise and accurate targeting of lesions. The demand for fixed tables is driven by their reliability and the ability to support complex biopsy procedures. They are particularly favored in settings where high patient throughput and comprehensive imaging capabilities are essential. Fixed stereotactic biopsy tables are designed to offer durability and are often equipped with advanced features such as adjustable height and positioning mechanisms, enhancing their versatility and usability in various biopsy procedures.

On the other hand, mobile stereotactic biopsy tables are gaining popularity due to their flexibility and ease of use. These tables are designed for portability, allowing them to be easily moved between different departments or even different healthcare facilities. Mobile tables ar

Here, the authors performed an in-silico analysis on a meta-dataset including gene-expression data from 5,342 clinically defined estrogen receptor-positive/ human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancers (BC), and DNA copy number/mutational and proteomic data, to determine whether the therapeutic response of ER+/HER2- breast cancers differs according to the molecular basal or luminal subtype.Data access: The dataset Breast_cancer_classifications.csv supporting figure 1, table 1, and supplementary tables 1-3 is publicly available in the figshare repository as part of this data record. This study used and analysed 36 publicly available datasets that are all listed in Supplementary table 8 and are cited from the data availability statement of the published article.Study aims and methodology: To evaluate the response and/or potential vulnerability to hormone treatment (HT) and other systemic therapies of BC, and to assess the degree of difference between basal and luminal breast cancer subtypes, the authors performed an in-silico analysis of a meta-dataset including gene expression data from 8,982 non-redundant BCs and DNA copy number/mutational and proteomic data from TCGA. The aim was to compare the Basal versus Luminal samples. Out of the 8,982 samples of the database, 6,563 were defined as ER+ (5,342 according to immunohistochemistry (IHC) and 1,221 according to inferred stratus).The authors analysed breast cancer gene expression data pooled from 36 public datasets (the publicly available datasets are listed in supplementary table 8), comprising 8,982 invasive primary BCs. The pre-analytic data processing was done as described previously in https://doi.org/10.1038/s41416-018-0309-1. Please refer to the published article for more details on the methodology and statistical analysis.Data supporting the figures, tables and supplementary tables in the published article: Data supporting figure 1, table 1, and supplementary tables 1-3: Dataset Breast_cancer_classifications.csv is in .csv file format. The dataset includes histo-clinical and molecular data of the tumors analysed in study, and is part of this data record.Data supporting supplementary table 4: Dataset genome.wustl.edu_BRCA.IlluminaGA_DNASeq.Level_2.3.2.0.tar.gz.1 is a tar archive gz compressed of maf format files. This dataset was accessed through the Genomic Data Commons (GDC) Data Portal and can be downloaded directly here: https://api.gdc.cancer.gov/data/afaf2790-04d4-453a-8c1b-75cf42ffd35f.Data supporting supplementary table 5: Dataset gdc_manifest.txt consists of gz archives of txt format files. The file was accessed through the GDC Data Portal here : https://portal.gdc.cancer.gov/repository?facetTab=files&filters={"op":"and","content":[{"op":"in","content":{"field":"cases.project.project_id","value":["TCGA-BRCA"]}},{"op":"in","content":{"field":"files.access","value":["open"]}},{"op":"in","content":{"field":"files.analysis.workflow_type","value":["HTSeq - Counts"]}},{"op":"in","content":{"field":"files.experimental_strategy","value":["RNA-Seq"]}}]}&searchTableTab=filesData supporting supplementary table 6: Dataset Table S5_Revised.xlsx is in .xlsx file format and is part of the supplementary information files of the published article.Data supporting supplementary table 7: Dataset BRCA.RPPA.Level_3.tar is a tar archive of txt format files. The file was accessed through the GDC Data Portal and can be downloaded directly here: https://api.gdc.cancer.gov/data/85988e1b-4f7d-493e-96ae-9eee61ac2833.

Radiotherapy Market Outlook

The global radiotherapy market is poised to experience robust growth over the forecast period, with an estimated market size of USD 7.6 billion in 2023, projected to reach approximately USD 15.4 billion by 2032, representing a compound annual growth rate (CAGR) of 8.2%. This growth is primarily driven by the increasing prevalence of cancer worldwide, advancements in radiotherapy technologies, and a shift towards non-invasive treatment modalities. As the global burden of cancer continues to rise, there is an escalating demand for effective treatment options, and radiotherapy has emerged as a cornerstone in cancer management due to its efficacy in reducing tumor size and controlling disease progression.

One of the key growth factors in the radiotherapy market is the technological advancements that have significantly improved the precision and effectiveness of radiotherapy treatments. Innovations such as Intensity-Modulated Radiotherapy (IMRT), Image-Guided Radiotherapy (IGRT), and Volumetric Modulated Arc Therapy (VMAT) have revolutionized treatment protocols by enabling targeted therapy that minimizes damage to surrounding healthy tissues. These technological strides have enhanced patient outcomes, reduced side effects, and expanded the therapeutic scope of radiotherapy, thereby driving its adoption across healthcare facilities globally. Moreover, continuous research and development endeavors focusing on integrating artificial intelligence and machine learning into radiotherapy are expected to further propel market growth.

The increasing government initiatives and funding to improve cancer care infrastructure is another significant growth driver in the radiotherapy market. Governments across various regions are investing in healthcare infrastructure development, with a particular focus on increasing access to advanced cancer treatment technologies. The establishment of specialized cancer treatment centers and the provision of subsidies for the adoption of advanced radiotherapy equipment are contributing factors. Additionally, public-private partnerships are playing a pivotal role in enhancing the accessibility and affordability of radiotherapy services, particularly in developing regions, thereby contributing to market expansion.

The aging population and changes in lifestyle are contributing to the rising incidence of cancer, thereby fueling the demand for radiotherapy. As the global population continues to age, the number of individuals susceptible to cancer is increasing, necessitating effective treatment solutions. Furthermore, lifestyle-related risk factors such as smoking, sedentary behavior, and unhealthy diets are exacerbating the cancer burden, further driving the demand for radiotherapy. The increasing awareness about early cancer detection and treatment is also supporting market growth, as patients and healthcare providers alike are recognizing the benefits of radiotherapy in managing cancer effectively.

Regionally, North America holds a significant share of the global radiotherapy market, attributed to the region's well-established healthcare infrastructure, high adoption rate of advanced technologies, and robust research and development capabilities. The presence of leading market players and favorable reimbursement policies further support market growth in this region. Meanwhile, the Asia Pacific region is anticipated to exhibit the fastest growth during the forecast period, driven by increasing healthcare expenditure, improving healthcare infrastructure, and a growing prevalence of cancer. The expanding middle-class population and increasing awareness about cancer treatment options are also contributing factors. Europe and Latin America are also witnessing steady growth, supported by advancements in radiotherapy technologies and government initiatives to enhance cancer care services.

In the realm of radiotherapy, the role of Radiation Therapy Positioning Tables is becoming increasingly significant. These tables are essential for ensuring precise patient positioning during treatment, which is crucial for the accuracy and effectiveness of radiotherapy. With advancements in imaging and treatment delivery, positioning tables have evolved to offer enhanced stability and flexibility, accommodating a wide range of patient anatomies and treatment sites. The integration of these tables with advanced imaging technologies allows for real-time adjustments,

According to Cognitive Market Research, the global Her2 Antibodies Market size will be USD 9351.4 million in 2025. It will expand at a compound annual growth rate (CAGR) of 5.50% from 2025 to 2033.

North America held the major market share for more than 37% of the global revenue with a market size of USD 3460.02 million in 2025 and will grow at a compound annual growth rate (CAGR) of 14.0% from 2025 to 2033.
Europe accounted for a market share of over 29% of the global revenue with a market size of USD 2711.91 million.
APAC held a market share of around 24% of the global revenue with a market size of USD 2244.34 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.5% from 2025 to 2033.
South America has a market share of more than 3.8% of the global revenue with a market size of USD 355.35 million in 2025 and will grow at a compound annual growth rate (CAGR) of 4.5% from 2025 to 2033.
Middle East had a market share of around 4% of the global revenue and was estimated at a market size of USD 374.06 million in 2025 and will grow at a compound annual growth rate (CAGR) of 4.8% from 2025 to 2033.
Africa had a market share of around 2.2% of the global revenue and was estimated at a market size of USD 205.73 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.2% from 2025 to 2033.
Pertuzumab the fastest growing segment of the Her2 Antibodies Market industry

Market Dynamics of Her2 Antibodies Market

Key Drivers for Her2 Antibodies Market

Government Initiatives To Improve Breast Cancer Care And Treatment Boost her2 antibodies Market

Government initiatives to improve breast cancer care and treatment are expected to drive future growth in the HER2 antibody market. These initiatives include policies, funding, and programs to improve the accessibility, affordability, and quality of care for people with breast cancer. These initiatives advance patient care and outcomes by increasing access to HER2 antibodies, a critical treatment for HER2-positive breast cancer, via subsidized programs and research funding. For instance, in February 2023, the World Health Organization (WHO) released a new Global Breast Cancer Initiative Framework, which outlines a strategy for saving 2.5 million lives from breast cancer by 2040. As a result, government efforts to improve breast cancer care are driving the HER2 antibody market.

https://www.who.int/news/item/03-02-2023-who-launches-new-roadmap-on-breast-cancer”/

Increasing Incidence Of Breast Cancer Cases Fuels her2 antibodies Market

The rising global incidence of breast cancer cases is expected to drive growth in the HER2 antibodies market over the forecast period. For instance, in January 2022, the American Cancer Society predicted that there would be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the United States, equating to approximately 1,670 deaths per day. Breast cancer is one of the four most common types of cancer worldwide, accounting for a sizable proportion of new cancer cases. As a result, the rise in global breast cancer incidence rates is expected to drive up demand for HER2 antibodies in the coming years.

https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html#:~:text=Estimated%20numbers%20of%20new%20cancer,factors%2C%20early%20detection%2C%20and%20treatment”/

Restraint Factor for the Her2 Antibodies Market

High cost of HER2 antibody therapies Limit Market Growth

The high cost of HER2 antibody treatments significantly impedes market expansion by limiting patient access to these life-changing therapies. Most patients with HER2-positive breast cancer may be discouraged by the cost of these therapies, forcing them to postpone or discontinue treatment. This is exacerbated in areas with limited healthcare coverage or inadequate insurance coverage for such advanced therapies. As a result, the premium price can create disparities in treatment access, affecting overall patient outcomes and limiting the market's growth potential. To increase patient access and market growth, HER2 antibody therapies must be made more affordable. Introduction of the Her2 Antibodies Market

HER2 antibodies are used in the treatment of HER2-positive breast cancer. HER2 is part of the human epidermal growth factor family. Overexpression of the HER2 oncogene causes the development and progression of some types...

The list of circRNAs identified in colorectal cancer

Recurrence of estrogen receptor (ER)-positive breast tumors despite definitive, curative-intent adjuvant therapy is thought to be due to enrichment of tumor initiating cells (TIC) during endocrine therapy (ET). Recently, it was identified that by antagonizing the ER, ET promotes the rapid degradation of the death-associated factor 6 (DAXX) protein, which is necessary and sufficient to potently inhibit TICs. Thus, the challenge is to identify an agent that increases DAXX protein levels to inhibit TICs and prevents proliferation of the tumor. Phytoestrogens (naringenin, resveratrol, genistein, apigenin, and quercetin), which are partial estrogens, were screened for DAXX protein expression, anti-TIC and anti-proliferative efficacy in vitro and in vivo. Specific DAXX-inducing phytoestrogens were also tested to assess selectivity towards ERα and/or ERβ.Data access: The raw and processed datasets supporting figures 1-9, generated during the current study, are publicly available in the figshare repository as part of this data record (https://doi.org/10.6084/m9.figshare.12601724). Additional datasets supporting supplementary figures 1-4, will be made available on reasonable request from the corresponding author Dr. Clodia Osipo, email address: cosipo@luc.edu. Uncropped Western blots are available as part of the supplementary figures.Study approval: All animal studies were approved by Loyola University Chicago’s Institutional Animal Care and Use Committee (IACUC). Study aims and methodology: In this study, the authors hypothesized that phytoestrogens may be sufficient to increase DAXX protein levels in an ERα/β-dependent manner without inducing total breast tumor cell proliferation. They tested the effects of a variety of phytoestrogens (naringenin, genistein, apigenin, resveratrol, and quercetin) on total cell proliferation of ER+ MCF-7 (wild-type p53) and T47D (mutant p53) cells, DAXX protein expression, and TIC survival in vitro and in vivo. They also tested if phytoestrogens may be more selective towards ERα or ERβ by using selective agonists or antagonists in vitro.Cell lines used: ER+ MCF-7 (wild-type p53) and T47D (mutant p53) cells.Patient-derived xenografts (PDXs) used: The PDX BCM-5097 was purchased from The Baylor College of Medicine. This primary breast tumor was originally derived from a female Caucasian patient with metastatic disease following pre-surgical docetaxel treatment. It is positive for both the ER and progesterone receptor (PR) and negative for overexpression of human epidermal growth receptor 2 (HER2).The following techniques are described in more detail in the published article: RNA interference, Cycloheximide DAXX protein decay, Western blot analysis, Real time polymerase chain reaction (PCR), total cell proliferation, mammosphere forming assay, ex vivo analysis of TIC-survival, tumor initiating potential in vivo.Data supporting the figures and supplementary figures in the published article: All the datasets supporting figures 1-9 and supplementary figures 1-4, generated during the current study are listed in the data file Peiffer et al.xlsx. Datasets supporting figures 1-9 are in Excel (.xlsx), GraphPad (.pzf and .pzfx) and power point (.pptx) file format, and are part of this figshare data record.Software needed to access data: Files in. pzf can be opened by GraphPad Prism 4 or later. Files in .pzfx file format can be opened only by GraphPad Prism 5 or later.

The rate of liver cancer diagnoses in the United States increases with age. As of 2021, those aged 75 to 79 years had the highest rates of liver cancer. Risk factors for liver cancer include smoking, drinking alcohol, being overweight or obese, and having diabetes. Who is most likely to get liver cancer? Liver cancer in the United States is much more common among men than women. In 2021, there were 12.3 new liver cancer diagnoses among men per 100,000 population, compared to just five new diagnoses per 100,000 women. Concerning race and ethnicity, non-Hispanic American Indians and Alaska Natives and Hispanic have the highest rates of new liver cancer diagnoses. The five-year survival rate for liver cancer in the United States is around 22 percent, however, this rate is much higher among non-Hispanic Asian and Pacific Islanders than other races and ethnicities. Non-Hispanic Asian and Pacific Islanders have a 33 percent chance of surviving the next five years after a liver cancer diagnosis. Deaths from liver cancer In 2020, there were an estimated 20,262 deaths in the United States due to liver cancer. However, the death rate for liver cancer has decreased over the past few years. In the period 1999 to 2020, the death rate for liver cancer reached a high of five deaths per 100,000 population in 2015 but dropped to 4.6 deaths per 100,000 population by 2020. It is estimated that in 2024, there will be over 19,000 liver and intrahepatic bile duct cancer deaths among men in the United States and 10,700 such deaths among women.

Supplementary Tables 1-6. This file contains primers and siRNAs sequences used in this study, differentially expressed circRNAs in lung adenocarcinoma, and altered gene locus. Detail results about the correlation between circPRKCI expression and clinicopathologic characteristics, survival of lung adenocarcinoma patients are also included.

Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 (%) in United States was reported at 13.7 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. United States - Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 - actual values, historical data, forecasts and projections were sourced from the World Bank on July of 2025.

The global market for radiation therapy positioning tables is experiencing robust growth, driven by the increasing prevalence of cancer and the rising demand for advanced radiotherapy techniques. The market's expansion is fueled by technological advancements leading to more precise and efficient treatment delivery, improved patient comfort during prolonged procedures, and the integration of sophisticated imaging capabilities directly into the tables. Key trends include the increasing adoption of electrically adjustable tables offering enhanced flexibility and precision compared to manual counterparts, and a shift towards integrated systems that streamline workflows and minimize treatment time. The hospital segment dominates the application landscape, reflecting the concentration of radiation therapy services in larger healthcare facilities. While North America and Europe currently hold significant market share, Asia-Pacific is projected to witness substantial growth driven by rising healthcare expenditure and expanding cancer care infrastructure in emerging economies like China and India. However, the high cost of advanced tables and the need for specialized personnel to operate and maintain them pose significant restraints to wider adoption, particularly in resource-constrained settings. The competitive landscape is characterized by established players like Accuray, Elekta, and Varian, alongside emerging companies focusing on innovation and cost-effective solutions. This dynamic interplay of factors suggests a continued expansion of the market, albeit with regional variations and a focus on technological innovation to address the cost and accessibility challenges. The forecast period (2025-2033) anticipates a sustained CAGR, reflecting ongoing technological advancements and the increasing prevalence of cancer globally. While estimating precise figures without specific data is impossible, a logical assumption based on industry trends would place the market size at approximately $2 billion in 2025, growing steadily throughout the forecast period. Regional differences will likely persist, with North America and Europe retaining a larger share initially, while the Asia-Pacific region experiences faster growth rates. The increasing integration of advanced imaging and treatment planning capabilities within the positioning tables is likely to drive premium pricing in the electric adjustment segment, potentially impacting the overall market value. Continued research and development in areas such as robotic assistance and AI-driven treatment optimization will further shape market dynamics in the coming years. Regulatory approvals and reimbursement policies will also play a crucial role in influencing market growth across different regions.